CAJ | 학술논문

目的：以温肾健脾、化气行水为治疗大法，探讨温肾化气丸治疗脾肾阳虚型慢性肾小球肾炎的临床疗效。方法将60例患者随机分为两组，治疗组（30例）给予口服温肾化气丸，6g/次，3次/d。对照组（30例）给予口服济生肾气丸，6g/次，3次/d。疗程8周。观察比较两组的疗效及尿蛋白、尿潜血、肌酐、尿素氮的变化情况。结果治疗组总有效率为86.7%，与对照组总有效率63.3%比较，差异有统计学意义（P＜0.05）。在尿潜血、24h尿蛋白定量、尿蛋白改善上，治疗组优于对照组，差异有统计学意义（P＜0.05）。在改善CRE上治疗组优于对照组，在改善BU年上两组间无显著差异。在安全性上，两组均未发生不良反应。结论采用温肾健脾、化气行水法，以温肾化气丸治疗脾肾阳虚型慢性肾小球肾炎临床疗效显著。
목적：이온신건비、화기행수위치료대법，탐토온신화기환치료비신양허형만성신소구신염적림상료효。방법장60례환자수궤분위량조，치료조（30례）급여구복온신화기환，6g/차，3차/d。대조조（30례）급여구복제생신기환，6g/차，3차/d。료정8주。관찰비교량조적료효급뇨단백、뇨잠혈、기항、뇨소담적변화정황。결과치료조총유효솔위86.7%，여대조조총유효솔63.3%비교，차이유통계학의의（P＜0.05）。재뇨잠혈、24h뇨단백정량、뇨단백개선상，치료조우우대조조，차이유통계학의의（P＜0.05）。재개선CRE상치료조우우대조조，재개선BU년상량조간무현저차이。재안전성상，량조균미발생불량반응。결론채용온신건비、화기행수법，이온신화기환치료비신양허형만성신소구신염림상료효현저。
ObjectiveUseing the Wenshen Jianpi,Huaqi Xingshui for treatment method, to discuss the clinical effect of the Wenshen Huaqi pill in treating spleen kidney yang deficiency syndrome of chronicglomerulonephritis.Methods 60 patients were randomly divided into two groups, the treatment group (30 cases) treated with oral administration of the Wenshen Huaqi Pill, 6g/time, 3 times/day. The control group (30 cases) treated with oral administration of Jisheng Shenqi Pill, 6g/time, 3 times/day. Treatment of 8w. To observe the changes of the two groups were compared the efficacy and urinary protein, urine occult blood, serum creatinine, urea nitrogen.Results The total effective rate in the treatment group was 86.7%, and the control group, the total efficiency of 63.3%comparison, there was significant difference(P<0.05). In the urine occult blood, 24h urinary protein, improve, the treatment group than the control group,there are significant differences(P<0.05). In the improvement of CRE in treatment group than in control group, in the improvement of BUN with no significant difference between two groups. On the security, the two groups were no adverse reaction.Conclusion The use of Wenshen Jianpi,Huaqi Xingshui, to the clinical curative effect of Wenshen Huaqi Pill in treating spleen kidney yang deficiency syndrome of chronic glomerulonephritis significantly.